Eyenovia to Participate in the 33rd Annual Roth Conference

Rhea-AI Summary

Eyenovia, Inc. (NASDAQ: EYEN), a clinical-stage ophthalmic company, will participate in the 33rd Annual Roth Conference from March 15-17, 2021. They will host virtual one-on-one meetings to connect with institutional investors. Eyenovia focuses on developing advanced therapeutics utilizing its proprietary microdose array print (MAP™) technology, specifically targeting presbyopia, myopia progression, and mydriasis. For more information, visit www.eyenovia.com.

NEW YORK, March 10, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced that management will participate in the 33rd Annual Roth Conference, which will be held on March 15-17, 2021. Management will host virtual one-on-one meetings during the conference.

Institutional investors interested in a one-on-one meeting with Eyenovia management should contact their ROTH institutional sales representative.

About Eyenovia, Inc.

Eyenovia, Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology. Eyenovia is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis. For more Information, visit www.eyenovia.com.

Eyenovia Contact:
Eyenovia, Inc.
John Gandolfo
Chief Financial Officer
jgandolfo@eyenovia.com

Eyenovia Investor Contact:
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
(646) 751-4363

Eyenovia Media Contact:
Diana Soltesz
Pazanga Health Communications
dsoltesz@pazangahealth.com
(818) 618-5634

FAQ

When will Eyenovia participate in the Roth Conference 2021?

Eyenovia will participate in the 33rd Annual Roth Conference from March 15-17, 2021.

What is Eyenovia's focus in ophthalmology?

Eyenovia focuses on developing advanced therapeutics for presbyopia, myopia progression, and mydriasis.

How can investors meet Eyenovia management during the conference?

Institutional investors can contact their ROTH institutional sales representative to arrange one-on-one meetings.

What technology does Eyenovia use in its product development?

Eyenovia uses its proprietary microdose array print (MAP™) platform technology for product development.

What is the stock symbol for Eyenovia?

The stock symbol for Eyenovia is EYEN.